Physician profile
David A Rawitscher
NPI 1700873247
$122,249.39
in general payments reported to CMS, 2019-2025
48 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $18K · 2021: $2,309 · 2022: $16K · 2023: $12K · 2024: $6,782 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $13K · Consulting Fee: $6,300 · Education: $4,520 · Travel and Lodging: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,957.50 |
| Food and Beverage | $12,617.84 |
| Consulting Fee | $6,300.00 |
| Education | $4,520.22 |
| Travel and Lodging | $1,227.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26,108.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $24,843.70 | 2019-2023 | Xarelto |
| Itamar Medical INC | $14,433.36 | 2021-2025 | Watchpatone |
| E.R. Squibb & Sons, L.L.C. | $12,772.59 | 2021-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $11,734.32 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11,569.65 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $7,584.65 | 2019-2025 | |
| Abbott Laboratories | $4,184.45 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Pfizer INC. | $1,166.59 | 2020-2025 | |
| Novo Nordisk INC | $743.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $726.26 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $689.28 | 2023-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $660.18 | 2019-2025 | Amvuttra, Onpattro |
| Celgene Corporation | $600.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $581.29 | 2021-2025 | Farxiga, Wainua, Brilinta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rawitscher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.